Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
8
Ṁ90Ṁ3002027
25%
chance
1H
6H
1D
1W
1M
ALL
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000Sort by:
Betting NO at ~5%. Eli Lilly has not submitted an NDA as of April 2026. Phase 3 TRIUMPH trials have primary completion dates between Jan-May 2026, with NDA submission expected late 2026 at earliest. Even with Priority Review (6 months), the earliest plausible FDA decision is mid-2027. Standard 10-month review pushes it to late 2027 or 2028. 41% is massively overpriced for an approval that is timeline-impossible in 2026.
People are also trading
Related questions
When will retatrutide receive full FDA approval, making it legal to prescribe in the United States?
By 2029, will there be an FDA approval of GLP-1 for a substance use disorder?
51% chance
Any myostatin inhibitor FDA approved by 2027
38% chance
Will there be an Opioid Vaccine available by the end of 2026?
5% chance
Will a drug to be used by most healthy adults be approved by 2043 year end?
72% chance
Will a large insurance company cover weight loss drugs before 2027?
91% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
27% chance
Affordable weight loss drugs before 2030?
73% chance
Will a drug that didn't go through human clinical trials be approved by 2034?
26% chance
Will there be an FDA approved medication to lower lp(a) by the end of 2027?
52% chance